Effect of Ayurveda formulation on Fatty Liver Disease.

A randomized controlled clinical study to evaluate the efficacy of Punarnavadi Kwatha and Phaltrikadi Kwatha in the management of Yakrut Vikara (Non Alcoholic Fatty Liver Disease) - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101675

Enrollment

Registered

2026-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with age group of equal or greater than 21 years and equal or less than 60 years of age irrespective of sex, occupation, and economic status. 2) Ultrasonographical evidence of fatty liver (not more than 1 month old). 3) Altered serum liver enzyme levels defined as serum AST (SGOT) and/or ALT (SGPT) greater than normal (35 - 40mg/dl) with raised lipid profile. 4) Subjects who are ready to sign the informed consent. 5) Subjects who are not registered in any other research project. 6) Subjects who can take medicine orally.

Exclusion criteria

Exclusion criteria: 1) Subjects with alcohol intake. 2) Subjects diagnosed with other liver diseases such as Viral hepatitis(A,B,C,D,E), auto immune hepatitis, Wilsons s disease, Alpha 1 antitrypsin deficiency, Haemochromatosis. 3) Subjects on long term hepatotoxic medication like acetaminophen, anabolic steroids, diclofenac, methotrexate. 4) Subjects currently participating in any other clinical trial (since last 6 month). 5) Pregnant and lactating women. 6) Subjects with ultrasonographical evidence of cirrhosis or necrosis of liver. 7) Subjects who had major surgery within 4 weeks prior to screening visit.

Design outcomes

Primary

Measure	Time frame
Improvement in ultrasonogram of abdomen.Timepoint: Day 0 and Day 75	—

Secondary

Measure	Time frame
Reduction in elevated liver enzymes. (SGOT, SGPT, GGT and ALP). Improvement in sr. triglyceride and fatty liver index. Improvement in Fasting Blood Sugar and Body Mass Index. Improvement in severity of sign and symptoms of Yakrut Vikara. (~Non-Alcoholic Fatty Liver Disease). 1 Hridkanthdaha (Epigastric discomfort) 2 Aruchi (Anorexia) 3 Udarashula (Abdominal pain) 4 Utklesha (Nausea) Timepoint: Day 0, 15, 30, 45, 60, 75	—

Measure

Time frame

Reduction in elevated liver enzymes. (SGOT, SGPT, GGT and ALP). Improvement in sr. triglyceride and fatty liver index. Improvement in Fasting Blood Sugar and Body Mass Index. Improvement in severity of sign and symptoms of Yakrut Vikara. (~Non-Alcoholic Fatty Liver Disease). 1 Hridkanthdaha (Epigastric discomfort) 2 Aruchi (Anorexia) 3 Udarashula (Abdominal pain) 4 Utklesha (Nausea) Timepoint: Day 0, 15, 30, 45, 60, 75

—

Countries

India

Contacts

Public ContactDr Rajendra Kumar Soni

Chaudhary Brahm Prakash Ayurved Charak Sansthan

dr.rajendrasoni@yahoo.com8506964826

Outcome results